Kura Oncology presents preliminary clinical and preclinical data for tipifarnib in the treatment of relapsed or refractory peripheral T-Cell
Kura Oncology announces data presentations for tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
Blueprint Medicines announces new Phase 1 clinical data for BLU-285 in advanced Gastrointestinal Stromal Tumors and plans to pursue expedited development in patients with a PDGFRα D842V mutation
Jounce Therapeutics presents Phase 1 data from ICONIC study of JTX-2011 in patients with advanced solid tumors at 2017 ASCO Annual Meeting
TRACON Pharmaceuticals presents positive clinical data from TRC105 and TRC102 studies at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
TRACON Pharmaceuticals announces clinical data presentations at upcoming ASCO annual meeting
TRACON Pharmaceuticals doses first patient in Phase I/II study of TRC253 in patients with prostate cancer
Jounce Therapeutics to present Phase 1 data from JTX-2011 ICONIC trial at 2017 american society of clinical oncology
Blueprint Medicines to present new data from ongoing Phase 1 clinical trial of BLU-285 in Patients with advanced GIST at 2017 ASCO annual meeting
Kura Oncology reports first quarter 2017 operational and financial results
Peloton Therapeutics initiates patient dosing in Phase 2 study of PT2385 for von Hippel-Lindau disease-associated kidney cancer
TRACON Pharmaceuticals announces publication in Blood of preclinical data indicating activity of TRC105 in acute myeloid leukemia and B-cell acute lymphoblastic leukemia
TRACON Pharmaceuticals reports first quarter financial results and provides corporate update
Jounce Therapeutics reports first quarter 2017 financial results
Sunesis Pharmaceuticals reports first quarter 2017 financial results and recent highlights
Kura Oncology to report first quarter 2017 financial results
Blueprint Medicines reports first quarter 2017 financial results
TRACON Pharmaceuticals to report first quarter company highlights and financial results on May 10, 2017
Sunesis Pharmaceuticals announces withdrawal of European Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed/refractory AML
Blueprint Medicines to report first quarter 2017 financial results on Wednesday, May 3, 2017
ASCO Annual MeetingChicago
3rd Annual Immuno-Oncology: BD&L and Investment ForumChicago
Boston CEO ConferenceBoston
The 2nd Annual Global Impact Investment ConferenceGeneva, Switzerland
Swiss Biotech DayBasel
Keep me updated about investment opportunities in the area of oncology and life sciences.
May 2017February 2017September 2016May 2016February 2016
Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time. A link to your subscription profile can be found in every newsletter email.
Newsletters * Nextech Invest News Preview
Salutation * Ms./Mrs. Mr. Company
Company
First name *
Surname *
Address
ZIP / City
Email *
* Compulsory fields
Your eMail have been successfully registered.
